This clinical trial is focused on studying the effectiveness and safety of a new treatment called Datopotamab deruxtecan (also known as Dato-DXd) for patients with a specific type of breast cancer known as triple-negative breast cancer (TNBC). This type of breast cancer is characterized by the absence of three common receptors known to fuel most breast cancer growths. The study is designed for patients whose cancer has either returned and cannot be surgically removed or has spread to other parts of the body, and who are not suitable for a type of treatment called PD-1/PD-L1 inhibitor therapy.

The trial will compare the new treatment, Datopotamab deruxtecan, with standard chemotherapy options, which include medications such as carboplatin, paclitaxel, capecitabine, and eribulin mesylate. These medications are commonly used in chemotherapy to treat various types of cancer by stopping the growth of cancer cells. The purpose of the study is to determine if the new treatment is more effective in prolonging the time patients live without their disease getting worse and in improving overall survival compared to the standard chemotherapy options.

Participants in the study will be randomly assigned to receive either the new treatment or one of the standard chemotherapy options. The treatment will be administered through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the participants’ health and response to the treatment over time to gather information on the effectiveness and safety of Datopotamab deruxtecan compared to the standard treatments. The trial aims to provide valuable insights into better treatment options for patients with triple-negative breast cancer.